首页 › 基金 › Frazier Life Sciences Management, L.P. › CLDX
Frazier Life Sciences Management, L.P. 对 CLDX 的持仓历史
CELLDEX THERAPEUTICS INC NEW · 医疗保健
Frazier Life Sciences Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 CLDX(CELLDEX THERAPEUTICS INC NEW)900,080 股,市值约 US$29.2M,约占其申报组合的 0.74%,在其申报持仓中市值排名第 25 位。 Frazier Life Sciences Management, L.P. 于 Q3 2026 首次申报该持仓。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Frazier Life Sciences Management, L.P. 对 CLDX 的持仓演变
Frazier Life Sciences Management, L.P. 于 Q3 2026 首次披露 CLDX 持仓:900,080 股(约 US$29.2M)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2026 | 900.08K | $29.17M | 新进 |
关于 CLDX 与 13F 数据
CLDX(CELLDEX THERAPEUTICS INC NEW)属于医疗保健行业。我们追踪的基金中还有 35 只申报持有 CLDX,申报仓位最大的包括:Kynam Capital Management, LP (US$164.2M), BAKER BROS. ADVISORS LP (US$83.1M), Deep Track Capital, LP (US$68.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CLDX 的基金
- Kynam Capital Management, LP 5.07M 股 · $164.19M · Q3 2026
- BAKER BROS. ADVISORS LP 2.56M 股 · $83.13M · Q3 2026
- Deep Track Capital, LP 2.13M 股 · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M 股 · $61.46M · Q3 2026
- Eversept Partners, LP 1.17M 股 · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M 股 · $37.61M · Q3 2026
- Elmind Capital, LP 1.11M 股 · $35.98M · Q3 2026
- Commodore Capital LP 1.00M 股 · $32.41M · Q3 2026
- Novo Holdings A/S 950.00K 股 · $30.79M · Q3 2026
- ADAR1 Capital Management, LLC 799.30K 股 · $25.91M · Q3 2026
- Trails Edge Capital Partners, LP 765.00K 股 · $24.79M · Q3 2026
更多关于 Frazier Life Sciences Management, L.P.
常见问题
How long has Frazier Life Sciences Management, L.P. held CLDX?
Frazier Life Sciences Management, L.P. has disclosed CLDX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Frazier Life Sciences Management, L.P.'s current position in CLDX?
As of Q3 2026, Frazier Life Sciences Management, L.P. holds 900.08K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $29.17M, representing 0.74% of its reported portfolio and ranking #25.
Has Frazier Life Sciences Management, L.P. been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Frazier Life Sciences Management, L.P. newly opened its position in CLDX.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.